FDA Issues Urgent Alert Over Counterfeit HIV Test Kits Amid Broader Health Safety Concerns

The Food and Drugs Authority (FDA) of Ghana has issued an urgent public health alert following the discovery of falsified VISITECT CD4 Advanced Disease test kits circulating within the country. These counterfeit diagnostic tools, which are critical for managing the healthcare of persons living with HIV, pose a significant risk to the public. According to the FDA, the use of these bogus kits could lead to erroneous test results, potentially causing dangerous delays in life-saving treatments or sparking unnecessary psychological distress for patients who receive incorrect diagnoses.

Technical investigations by the Authority revealed several critical discrepancies that distinguish the counterfeit products from authentic versions. The falsified kits are identified by lot number 0001586 and incorrectly list Omega Diagnostics Limited as the manufacturer. In contrast, genuine VISITECT CD4 Advanced Disease kits are produced by AccuBio Limited and typically carry lot number 0002172. Furthermore, the FDA highlighted significant inconsistencies regarding manufacturing and expiry dates; while authentic kits bear a manufacturing date of July 2025 and an expiry of November 2026, the counterfeit versions falsely claim an August 2024 manufacturing date and a January 2027 expiry.

In response to this discovery, the FDA has mandated an immediate halt to the use of all test kits associated with the suspicious lot number 0001586. All healthcare facilities, laboratories, and providers have been strictly instructed to audit their current stocks and return any products bearing the falsified lot number to the nearest FDA office for safe and documented disposal. The Authority emphasized that healthcare professionals must be particularly vigilant, as the presence of these kits on the market is a direct threat to the integrity of HIV management protocols and patient safety across the nation.

Beyond the immediate threat of falsified diagnostics, the FDA is urging health professionals and the general public to report any suspicious medical products or activities to official regulatory channels. This alert comes as part of a broader movement within the Ghanaian healthcare sector toward increased patient safety and empowerment. In a related trend, health advocates and experts are also calling for a re-evaluation of established clinical practices, such as encouraging a return to more natural, upright birthing positions to improve maternal health outcomes. Together, these developments underscore a growing national focus on ensuring that medical interventions are both authentic and aligned with evidence-based best practices.